Relugolix

ORGOVYX is indicated for the treatment of adult patients with advanced prostate cancer.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: ORGOVYX is indicated for the treatment of adult patients with advanced prostate cancer.
Do not take if: ORGOVYX is contraindicated in patients with severe hypersensitivity to relugolix or to any of the product components.

Side effects, and when to stop

The following clinically significant adverse reactions are described elsewhere in the labeling:

QT/QTc Interval Prolongation.

Who should not take it

ORGOVYX is contraindicated in patients with severe hypersensitivity to relugolix or to any of the product components.

Storing it

Storage and Handling

Store ORGOVYX at room temperature. Do not store above 30°C (86°F).
Dispense to patients in original container only.
For bottles, keep container tightly closed after first opening.
Keep out of reach of children.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Relugolix; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/relugolix
APA 7th: sofidex. (2026, August 3). Relugolix. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/relugolix
AMA 11th: Relugolix. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/relugolix

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.